Research Spotlight: Implementation of a Lifestyle Dementia Prevention Intervention
What Question Were You Investigating?
Interventions that promote healthy lifestyles are critical for the prevention of Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD). However, knowledge of the best practices for implementing AD/ADRD prevention in healthcare settings remains limited.
In our recent study, we set out to investigate the barriers and facilitators to implementing a clinical trial of the “My Healthy Brain” AD/ADRD prevention intervention at Mass General Brigham (MGB).
This intervention is a virtual, group-based program for older patients (age 60+) with subjective cognitive decline who are at risk for AD/ADRD. Group members learn mindfulness and behavioral strategies to set goals to improve physical activity, sleep, nutrition, and other lifestyle factors linked to lower rates of AD/ADRD.
The goal of our study was to qualitatively identify the challenges and supportive factors impacting the acceptability, appropriateness and feasibility of this intervention within the healthcare setting based on focus groups with healthcare professionals.
What Were the Results?
Our team conducted five focus groups with 26 healthcare professionals (e.g., physicians, psychology, nursing) from five MGB clinics that treat older patients (e.g., memory care, psychiatry).
The study found widespread support for a randomized controlled trial (RCT) of the My Healthy Brain program aimed at AD/ADRD prevention.
Participants identified several barriers, including:
- Patient-related issues (stigma and lack of technological skills)
- Provider-related challenges (dismissiveness towards patients' concerns and doubts about behavior change capacity)
- Clinic limitations (time and resource constraints)
- Systemic issues within the larger healthcare system (underemphasis on prevention).
Despite these barriers, facilitators included strong support for the intervention and a general acknowledgment of the need for AD/ADRD prevention strategies.
Implementation strategies recommended by participants included:
- Developing tailored materials
- Training staff
- Obtaining buy-in from leadership
- Addressing stigmatized language and practices
- Identifying “champions” within the organization
- Integrating the intervention with existing workflows and resources
What are the Clinical Implications and Next Steps?
The study highlights the importance of addressing multi-level barriers to effectively implement dementia prevention interventions in healthcare settings.
The findings suggest that with proper strategies it is feasible to integrate lifestyle interventions like My Healthy Brain into clinical practice. This integration could lead to improved prevention efforts for AD/ADRD, ultimately benefiting older patients at risk.
The next steps for this research involve conducting a feasibility randomized controlled trial (RCT) of the My Healthy Brain program based on the insights gained from this study.
This trial will refine recruitment, enrollment, and retention procedures, further test the implementation strategies identified, and evaluate the program's impact on cognitive health outcomes.
Additionally, ongoing collaboration with healthcare professionals and adaptation of the intervention to address identified barriers will be crucial for successful implementation and broader adoption in diverse clinical settings.
To Participate in My Healthy Brain
Email: mghmyhealthybrain@mgb.org
Phone number: (617) 643-9406
Website: https://rally.massgeneralbrigham.org/study/mhb
Caption: Ryan Andrew Mace, PhD
# # #
NOTES FOR EDITORS
ARTICLE
Mace, R. A., Lyons, C., Cohen, J. E., Ritchie, C., Bartels, S., Okereke, O. I., Hoeppner, B. B., Brewer, J. A., & Vranceanu, A. M. (2024). Optimizing the Implementation of a Lifestyle Dementia Prevention Intervention for Older Patients in an Academic Healthcare System. Journal of Alzheimer's disease : JAD, 100(4), 1237–1259. https://doi.org/10.3233/JAD-240365
ABOUT THE JOURNAL OF ALZHEIMER’S DISEASE (JAD)
The Journal of Alzheimer's Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a Journal Impact Factor of 3.4 according to Journal Citation Reports™ (Clarivate, 2024). The journal is published by IOS Press, now part of Sage. www.j-alz.com
ABOUT IOS PRESS
IOS Press, now part of Sage, is an international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in health and life sciences (including neurosciences, medical informatics, cancer research, and rehabilitation) and computer sciences (including artificial intelligence, data science, and semantic web). In addition, we offer specialized services that support scientific advancement. www.iospress.com
ABOUT SAGE
Sage is a global academic publisher of books, journals, and library resources with a growing range of technologies to enable discovery, access, and engagement. Believing that research and education are critical in shaping society, 24-year-old Sara Miller McCune founded Sage in 1965. Today, we are controlled by a group of trustees charged with maintaining our independence and mission indefinitely. https://group.sagepub.com